Pediatric Urology
12 cases on vesicoureteral reflux prophylaxis, antenatal hydronephrosis management, pediatric neurogenic detrusor overactivity drug selection, onabotulinumtoxinA for oral-refractory disease, desmopressin/alarm therapy and third-line imipramine for enuresis, hormonal therapy before orchiopexy, preoperative androgen stimulation before hypospadias repair, asymptomatic bacteriuria on intermittent catheterization, adjunctive corticosteroids in pyelonephritis, stuttering priapism prevention in sickle cell disease, and valve-bladder pharmacotherapy — choose a case below to open its full multi-voice debate.
Two children with vesicoureteral reflux, evaluated the same week, sit on opposite ends of the trial evidence: a three-month-old with grade II reflux found before any infection, and a four-year-old with grade IV reflux, a second febrile UTI, and documented bladder-bowel dysfunction.
A five-week-old boy with the most severe grade of antenatal hydronephrosis has no vesicoureteral reflux on VCUG, which removes the usual reason to start prophylaxis without removing the dilation itself.
A seven-year-old girl with spina bifida on long-term oxybutynin develops a new classroom attention complaint the same term her assignments got harder, forcing a choice between a within-class switch, a different mechanism entirely, and simply waiting to see what a cognitive screen finds.
A ten-year-old boy with spina bifida who has failed his one tolerable oral agent, and has a wheelchair basketball tournament in ten weeks, forces the real question in this pivot into the open: not whether botulinum toxin works, but where it sits relative to augmentation cystoplasty.
An eight-year-old boy with monosymptomatic nocturnal enuresis wants to attend sleepaway camp in eight weeks, forcing a choice between the option that works faster and the one that holds up better once treatment stops.
An eleven-year-old girl who has completed full, adherent trials of both alarm therapy and desmopressin without a single dry night is a genuine candidate for third-line imipramine — a drug whose real danger is measured in her four- and six-year-old brothers' bathroom, not just her own bloodstream.
Two boys with undescended testes sit on opposite sides of the AUA-versus-European guideline split: one with a straightforward unilateral, palpable testis, and one with bilateral, high, nonpalpable testes and a family who already asked about hormones before anyone raised it.
A fourteen-month-old boy with penoscrotal hypospadias and a below-percentile glans forces a decision the pooled literature makes look easy and the severity-stratified literature makes look genuinely contested: whether preoperative androgen stimulation helps or harms a repair this proximal.
A nine-year-old girl on clean intermittent catheterization has a positive surveillance urine culture and no symptoms at all, which the stewardship evidence says not to treat and her altered bladder sensation makes genuinely harder to trust.
A three-year-old girl with a high-risk early DMSA finding, and parents who found the steroid literature before the team raised it, sits directly on top of a real disagreement between an older positive meta-analysis and the largest, most rigorous trial to date.
A fifteen-year-old boy with sickle cell disease and increasingly frequent stuttering priapism has asked directly whether treatment could affect how tall he still grows, which every option on a case-series-only evidence base has to answer honestly, not just the hormonal ones.
A five-year-old boy with valve bladder syndrome after infant posterior urethral valve ablation has urodynamics showing both a storage-pressure problem and an emptying problem at once, which a small pilot trial suggests may need two different drugs rather than one.